17V Stock Chart & Stats
€0.73
-€0.02(-3.45%)
At close: 4:00 PM EST
€0.73
-€0.02(-3.45%)
Day’s Range― - ―
52-Week Range€0.58 - €0.83
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€98.23M
Enterprise Value€51.47
Total Cash (Recent Filing)€34.17M
Total Debt (Recent Filing)€667.00K
Price to Earnings (P/E)15.9
Beta0.18
Next Earnings
Nov 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding120,713,240
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.04
Price to Sales (P/S)2.40
P/FCF Ratio-273.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€494.45K
Bulls Say, Bears Say
Bulls Say
Improved Profitability (2025)The company delivered positive EBIT and materially higher net income in 2025, indicating an inflection in core earnings power. Sustained operating profitability supports reinvestment, strengthens ability to fund growth or contracts, and reduces reliance on external financing over the medium term.
De-risked Balance SheetDebt falling to roughly £0.7m materially reduces financial risk and interest burden, increasing flexibility for M&A, R&D, or working-capital support. A strong equity base relative to debt provides resilience to revenue cycles and preserves strategic optionality over the next several quarters.
Diversified Revenue ModelHaving both branded OTC products and third-party contract manufacturing diversifies revenue and cash sources. Contract manufacturing offers recurring factory utilization and service fees, while branded sales allow margin upside from brand building — a structural buffer versus single-stream players.
Bears Say
Volatile Revenue And MarginsRevenue swings and gross-profit stagnation despite a revenue rebound indicate exposure to volatile demand or unfavorable mix. Persistent revenue and margin variability undermines predictability of earnings and complicates planning for inventory, pricing, and long-term investment decisions.
Inconsistent Cash ConversionA reversal to negative operating and free cash flow in 2025 weakens confidence in cash-generation durability. If working-capital needs or one-offs recur, the firm may face liquidity pressure or need to use reserves, curtail investment, or seek external funding, constraining strategic moves.
Weak Historical Returns On EquityLarge equity relative to debt hasn’t consistently translated to returns: weak/negative ROE in 2024 points to inefficient capital use or low-margin operations. Persistently low returns could limit shareholder value creation and make it harder to justify reinvestment at scale.
Venture Life News
17V FAQ
What was Venture Life Group PLC’s price range in the past 12 months?
Venture Life Group PLC lowest stock price was €0.57 and its highest was €0.82 in the past 12 months.
What is Venture Life Group PLC’s market cap?
Venture Life Group PLC’s market cap is €98.23M.
When is Venture Life Group PLC’s upcoming earnings report date?
Venture Life Group PLC’s upcoming earnings report date is Nov 30, 2026 which is in 127 days.
How were Venture Life Group PLC’s earnings last quarter?
Venture Life Group PLC released its earnings results on Mar 31, 2026. The company reported €0.032 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Venture Life Group PLC overvalued?
According to Wall Street analysts Venture Life Group PLC’s price is currently Overvalued.
Does Venture Life Group PLC pay dividends?
Venture Life Group PLC does not currently pay dividends.
What is Venture Life Group PLC’s EPS estimate?
Venture Life Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Venture Life Group PLC have?
Venture Life Group PLC has 120,713,240 shares outstanding.
What happened to Venture Life Group PLC’s price movement after its last earnings report?
Venture Life Group PLC reported an EPS of €0.032 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.311%.
Which hedge fund is a major shareholder of Venture Life Group PLC?
Currently, no hedge funds are holding shares in DE:17V
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Venture Life Stock Smart Score
Company Description
Venture Life Group PLC
Established in Bracknell, UK, in 2005, Venture Life Group plc is an international developer and marketer of diverse health and personal care items. The company's portfolio spans oral care products, dietary supplements, medical devices, dermo-cosmetics, and topical applications, serving a global market across the United Kingdom, various European countries (including the Netherlands, Germany, Italy, and Switzerland), and China. Operating through its distinct Venture Life Brands and Customer Brands divisions, the company offers a comprehensive array of solutions. These include advanced neurology-focused nutritional supplements such as NeuroAge, NeuroAge Sleep, and NeuroAge NRG, designed to enhance alertness, cognitive abilities, and mental acuity. For hair health, Original Bioscalin addresses hair loss, thinning, and baldness. The Myco Clear range provides antifungal nail solutions, comprising a Fungal Nail Solution for treatment and prevention, and a Fungal Nail Cleanser for foot and hand hygiene. In the realm of oral care, UltraDEX is formulated to combat bad breath, while Dently Dual Action is a mouthwash engineered to effectively remove plaque and bacteria. For anal discomfort, Procto-eze plus offers relief for conditions like haemorrhoids and general irritation. Venture Life also features a dedicated women's healthcare line under the vonalei brand, which includes a refreshing gel for bacterial vaginosis, a vaginal cream for atrophy, a soothing cream-gel for candidiasis (thrush), and an intimate cleansing foam. Its dermo-cosmetic selections encompass the Rosa calma brand's Cleansing Foam, Cleansing Cream, and Serum, alongside the Lubatti Classic and Lubatti Anti-age skincare collections. These skincare lines are meticulously crafted to hydrate, nourish, and recondition the skin, helping to minimize the appearance of lines and wrinkles. The company distributes its extensive product offerings through a broad network that includes international partners, pharmacies, and major grocery retailers.